XML Financial LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XML Financial LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,237 shares of the biopharmaceutical company’s stock after selling 20 shares during the period. XML Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $1,191,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. iA Global Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 32.5% during the first quarter. iA Global Asset Management Inc. now owns 14,619 shares of the biopharmaceutical company’s stock worth $14,071,000 after acquiring an additional 3,584 shares in the last quarter. Hancock Whitney Corp raised its position in Regeneron Pharmaceuticals by 3.7% in the 1st quarter. Hancock Whitney Corp now owns 7,879 shares of the biopharmaceutical company’s stock worth $7,583,000 after purchasing an additional 278 shares during the period. Tidal Investments LLC lifted its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares during the last quarter. California State Teachers Retirement System boosted its position in Regeneron Pharmaceuticals by 1.0% during the first quarter. California State Teachers Retirement System now owns 173,049 shares of the biopharmaceutical company’s stock valued at $166,558,000 after buying an additional 1,648 shares during the period. Finally, Meiji Yasuda Life Insurance Co grew its stake in shares of Regeneron Pharmaceuticals by 17.6% during the first quarter. Meiji Yasuda Life Insurance Co now owns 3,501 shares of the biopharmaceutical company’s stock valued at $3,370,000 after buying an additional 525 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,074 shares of company stock worth $64,546,123. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ REGN traded up $13.95 during trading on Thursday, reaching $1,093.14. The company had a trading volume of 897,280 shares, compared to its average volume of 469,310. Regeneron Pharmaceuticals, Inc. has a 12-month low of $726.11 and a 12-month high of $1,106.16. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The business’s 50-day moving average is $1,039.23 and its 200 day moving average is $980.66. The stock has a market cap of $120.45 billion, a PE ratio of 31.88, a P/E/G ratio of 2.22 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on REGN shares. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the company a “buy” rating in a research report on Thursday, July 18th. Argus increased their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Piper Sandler boosted their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,074.95.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.